CA2813098C - Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e - Google Patents

Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e Download PDF

Info

Publication number
CA2813098C
CA2813098C CA2813098A CA2813098A CA2813098C CA 2813098 C CA2813098 C CA 2813098C CA 2813098 A CA2813098 A CA 2813098A CA 2813098 A CA2813098 A CA 2813098A CA 2813098 C CA2813098 C CA 2813098C
Authority
CA
Canada
Prior art keywords
antibody
cancer
sample
braf
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2813098A
Other languages
English (en)
French (fr)
Other versions
CA2813098A1 (en
Inventor
Hanswalter Zentgraf (Deceased)
Andreas Von Deimling
David Capper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Universitaet Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ, Universitaet Heidelberg filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of CA2813098A1 publication Critical patent/CA2813098A1/en
Application granted granted Critical
Publication of CA2813098C publication Critical patent/CA2813098C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2813098A 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e Active CA2813098C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38815810P 2010-09-30 2010-09-30
US61/388,158 2010-09-30
US201161503950P 2011-07-01 2011-07-01
US61/503,950 2011-07-01
PCT/EP2011/067092 WO2012042009A1 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Publications (2)

Publication Number Publication Date
CA2813098A1 CA2813098A1 (en) 2012-04-05
CA2813098C true CA2813098C (en) 2019-10-08

Family

ID=44789447

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2813098A Active CA2813098C (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Country Status (9)

Country Link
US (1) US9297812B2 (enExample)
EP (1) EP2622348B1 (enExample)
JP (1) JP5893037B2 (enExample)
CN (1) CN103403550B (enExample)
AU (1) AU2011310096B2 (enExample)
CA (1) CA2813098C (enExample)
DK (1) DK2622348T3 (enExample)
ES (1) ES2554678T3 (enExample)
WO (1) WO2012042009A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172744B (zh) * 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
JP6485854B2 (ja) * 2014-09-24 2019-03-20 国立研究開発法人国立循環器病研究センター 抗変異型プロテインｓ抗体、該抗体を含む診断用組成物、変異型ヒトプロテインｓの検出方法および該抗体を含むキット
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
JP6941688B2 (ja) 2017-06-29 2021-09-29 コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー 神経節膠腫が誘導された動物モデルならびに神経節膠腫およびこれに関連する疾患の診断用組成物
CN110183535A (zh) * 2018-12-17 2019-08-30 南京基诺米医疗科技有限公司 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
WO2022104200A1 (en) * 2020-11-16 2022-05-19 Agilent Technologies, Inc. Chimeric anti-human braf v600e antibodies and methods for making and using them
WO2024090265A1 (ja) * 2022-10-28 2024-05-02 株式会社biomy 情報処理装置、情報処理方法及びプログラム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6735531B2 (en) * 1996-10-07 2004-05-11 Lab Vision Corporation Method and apparatus for automatic tissue staining
AU2003286447A1 (en) * 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
US7811993B2 (en) 2005-06-29 2010-10-12 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
JP2009077712A (ja) 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
KR20100065189A (ko) 2007-09-11 2010-06-15 유니버시티 오브 매사추세츠 암을 치료하기 위한 인슐린­유사 성장 인자 결합 단백질 7

Also Published As

Publication number Publication date
EP2622348B1 (en) 2015-09-16
US20130266962A1 (en) 2013-10-10
ES2554678T3 (es) 2015-12-22
AU2011310096B2 (en) 2014-11-06
DK2622348T3 (en) 2015-12-14
JP5893037B2 (ja) 2016-03-23
AU2011310096A1 (en) 2013-04-18
WO2012042009A1 (en) 2012-04-05
CA2813098A1 (en) 2012-04-05
US9297812B2 (en) 2016-03-29
CN103403550B (zh) 2015-08-19
EP2622348A1 (en) 2013-08-07
JP2013543117A (ja) 2013-11-28
CN103403550A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
EP2438442B1 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
CA2813098C (en) Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e
JP6075881B2 (ja) 乳癌のバイオマーカー
CA3020650C (en) Ros kinase in lung cancer
US20120058492A1 (en) Method and a Kit To Detect Malignant Tumors and Provide a Prognosis
WO2011146945A2 (en) Alk and ros kinase in cancer
US20030190688A1 (en) Methods for detecting BCR-ABL signaling activity in tissues using phospho-specific antibodies
US20180017575A1 (en) Histone protein ubiquitination as a cancer biomarker
US20160341733A1 (en) Detection and treatment of cancer
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
US20130143231A1 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160830